CYTOCHROMA TO PRESENT AT UPCOMING INVESTOR CONFERENCES
MARKHAM, ON, Sept. 8 /PRNewswire/ - Cytochroma today announced that Charles W. Bishop, PhD, President and CEO, will be presenting a corporate overview at the following investor conferences:
- Baird's 2010 Health Care Conference at 10:30 AM EDT on Tuesday, September 14, 2010 at The St. Regis New York in New York City. - Stifel Nicolaus Healthcare Conference 2010 at 10:55 AM EDT on Friday, September 17, 2010 at the Four Seasons Hotel in Boston.
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD patients, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD patients. Cytochroma also has a portfolio of compounds that inhibit CYP24 in early stage development.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.